| P50 | author | Mariano Esteban | Q30004051 |
| | Giuseppe Pantaleo | Q88061163 |
| | Beatriz Perdiguero | Q112248161 |
| | Victoria Cepeda | Q114406489 |
| | Lucas Sánchez-Sampedro | Q114406490 |
| | Ernesto Mejías-Pérez | Q114406491 |
| | Benedikt Asbach | Q114406492 |
| | Karen V Kibler | Q114406493 |
| | Thierry Roger | Q40228404 |
| | Carmen E Gómez | Q42100464 |
| | Carlos Oscar Sanchez Sorzano | Q56027899 |
| | Thierry Calandra | Q56616768 |
| | Ralf Wagner | Q57979852 |
| | Juan Carlos Oliveros | Q59464072 |
| | Juan García-Arriaza | Q79782431 |
| P2093 | author name string | Bertram L Jacobs | |
| | Julie Delaloye | |
| | Cristina Sánchez | |
| | Victoria Jiménez | |
| P2860 | cites work | A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses | Q21135240 |
| | Poxvirus vectors as HIV/AIDS vaccines in humans | Q26995078 |
| | Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C | Q27306437 |
| | Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions | Q27320923 |
| | Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome | Q28389050 |
| | Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine | Q28482252 |
| | Improved NYVAC-based vaccine vectors | Q28742982 |
| | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 |
| | Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). | Q33320536 |
| | Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies | Q33440600 |
| | Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens | Q33627613 |
| | Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses | Q33838030 |
| | Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein | Q34182371 |
| | Applications of pox virus vectors to vaccination: an update | Q34403246 |
| | Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens | Q34465228 |
| | SPICE: exploration and analysis of post-cytometric complex multivariate datasets | Q34769778 |
| | Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways | Q34796206 |
| | Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. | Q34880294 |
| | Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice | Q35943846 |
| | Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques | Q36397581 |
| | An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses | Q36446900 |
| | Enhancing poxvirus vectors vaccine immunogenicity. | Q36978452 |
| | The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys | Q37547241 |
| | Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. | Q37643731 |
| | MVA and NYVAC as vaccines against emergent infectious diseases and cancer. | Q37859845 |
| | Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine | Q39589039 |
| | Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model | Q39790409 |
| | Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. | Q40447904 |
| | Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines | Q41544688 |
| | NYVAC: a highly attenuated strain of vaccinia virus | Q41626050 |
| | HIV-1 gag proteins: diverse functions in the virus life cycle | Q43783202 |
| | NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients | Q44766920 |
| | Virus-like particles: a novel tool for the induction and monitoring of both T-helper and cytotoxic T-lymphocyte activity. | Q45676992 |
| | EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone | Q46576663 |
| | Mouse neurotoxicity test for vaccinia-based smallpox vaccines. | Q47823151 |
| | A comparative study of the pathogenesis of western equine and eastern equine encephalomyelitis viral infections in mice by intracerebral and subcutaneous inoculations. | Q48910022 |
| | EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. | Q54454033 |
| | HIV-1 p24 Gag-specific cytotoxic T-lymphocyte responses in mice | Q71528382 |
| | Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C | Q79561534 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| | HIV/AIDS | Q12199 |
| P304 | page(s) | 970-988 | |
| P577 | publication date | 2014-10-29 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles | |
| P478 | volume | 89 | |